Rosetta Genomics Interpace Diagnostics Q3 Revenues Up 38 Percent The company beat the consensus Wall Street estimate on the top line and guided to 2018 revenues of between $21 million and $22 million. Rosetta Genomics Files for Chapter 7 Bankruptcy Rosetta had disclosed that it intended to file for bankruptcy after its merger with Genoptix was not completed as planned. Rosetta Genomics Dispute With Genoptix Places Pending Merger in Jeopardy The merger, which was previously scuttled and later revived with Rosetta shareholder approval, was due to close on May 27. Rosetta Genomics Shareholders Approve Genoptix Merger Upon completion of the transaction, Rosetta will become a privately held subsidiary of Genoptix and its shares will cease to trade on the Nasdaq. Genoptix Inks Distribution Deal for Rosetta Genomics' Testing Services The deal comes as the firms try — for the second time — to close a merger that had previously failed to gain necessary approval from Rosetta shareholders. Feb 28, 2018 Rosetta Genomics, Genoptix Sign New Merger Agreement Feb 23, 2018 Rosetta Genomics, Genoptix Merger Terminated Dec 15, 2017 Genoptix to Acquire Rosetta Genomics for $10M Nov 30, 2017 Rosetta Genomics Receives Nasdaq Non-Compliance Letter Nov 8, 2017 Rosetta Genomics Receives Notification of Nasdaq Non-Compliance Oct 10, 2017 Rosetta Genomics Q2 Revenues Jump on Sales of Thyroid Assay Sep 28, 2017 Rosetta Genomics Initiates $2M Private Placement Sep 8, 2017 Rosetta Genomics Inks Deal to Sell PersonalizeDx for $2.9M Sep 5, 2017 Rosetta Genomics Announces Layoffs Aug 4, 2017 Rosetta Genomics Prices $2.7M Securities Offering May 23, 2017 Rosetta Genomics, Meir Medical Partner on microRNA Biomarker Study May 22, 2017 Rosetta Genomics Plans to Sell PersonalizeDx Business May 5, 2017 Rosetta Genomics Signs Brazilian Distribution Pact for Thyroid Test May 4, 2017 NYS Gives Final Approval for Rosetta Genomics' Thyroid Cancer Test May 2, 2017 Rosetta Genomics Realigns Strategy to Focus on Thyroid Test Mar 30, 2017 Rosetta Genomics Q4 Revenues Drop 44 Percent Mar 16, 2017 Rosetta Genomics Announces Reverse Stock Split Feb 23, 2017 Rosetta Genomics Completes Private Placement Tranche Feb 8, 2017 Rosetta Genomics Reports Q4 Sales Growth for Thyroid Nodule Test Dec 20, 2016 Rosetta Genomics Q3 Revenues Down 10 Percent Load More Breaking News SARS-CoV-2 Mutational Signature Associated With Mutagenic Antiviral Drug Biocartis Restructures Balance Sheet as H1 2023 Revenues Rise 12 Percent Rare Kidney Cancer Genomic Analysis Reveals Potential Target, Suggests Treatment SEC Concludes CareDx Investigation, Recommends No Enforcement Action Streck Quality Controls for DiaSorin's Luminex Sepsis Tests Receive FDA Clearance The Scan Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants. Small Study of Gene Editing to Treat Sickle Cell Disease In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms. Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema. Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.